J Cancer 2017; 8(16):3166-3172. doi:10.7150/jca.19060

Research Paper

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma

Gerardo Botti1*, Giosuè Scognamiglio1*, Laura Marra1, Antonio Pizzolorusso2, Maurizio Di Bonito1, Rossella De Cecio1, Monica Cantile1✉, Annarosaria De Chiara1

1. Pathology Unit, Istituto Nazionale Tumori Fondazione “G. Pascale”, via Mariano Semmola, 80131 Napoli, Italy;
2. Department of Muscle-skeletal Oncology, Istituto Nazionale Tumori Fondazione “G. Pascale”, via Mariano Semmola, 80131 Napoli, Italy.
* Equal contributors

Abstract

Angiosarcomas are rare malignant endothelial-cell tumors of vascular or lymphatic origin, and are among the most aggressive subtypes of soft-tissue sarcomas. The prognosis is poor and treatment is challenging in many cases. PD-1/PD-L1 pathway plays a critical role in immune escape of tumor cells. Recent studies described that PD-L1 is widely expressed in various types of cancer, providing the basis for the development of PD1/PD-L1 antibodies as anti-cancer immunotherapy. Despite the well-known potential of PD-L1 as prognostic and predictive biomarker, only few studies described its IHC expression in cancer subtypes for the extreme difficulty in developing standard protocol with the different antibody clones available.

We analyzed the IHC expression of PD-L1 on a series of angiosarcomas at different body location, showing its aberrant expression in about 66% of samples with no relation with prognosis. Our study allowed us to correctly define PD-L1 staining in angiosarcoma tumor tissues with final purpose to stratify patients for immune checkpoint inhibitors therapies.

Keywords: angiosarcoma, PD-L1, IHC evaluation.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Botti G, Scognamiglio G, Marra L, Pizzolorusso A, Di Bonito M, De Cecio R, Cantile M, De Chiara A. Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma. J Cancer 2017; 8(16):3166-3172. doi:10.7150/jca.19060. Available from http://www.jcancer.org/v08p3166.htm